Prostamax is a high-purity, research-grade synthetic tetrapeptide developed for laboratory studies of prostate tissue biology, cellular aging processes, and gene-level regulation in target cells. It belongs to the short peptide bioregulator class associated with the work of Vladimir Khavinson and colleagues.
Molecular Composition and Mechanistic Profile
Prostamax (Lys-Glu-Asp-Pro, or KEDP): A four-amino-acid peptide with the sequence lysine-glutamic acid-aspartic acid-proline. Molecular weight is approximately 487.5 Da (formula C20H33N5O9). It was designed as a synthetic analog linked to prostate tissue extracts within the Khavinson bioregulator series.
Structural characteristics: The small size allows cell penetration and proposed interactions with nuclear components. Research models suggest it can influence chromatin structure by promoting decondensation of tightly packed DNA regions, particularly in aged cells. This may support reactivation of certain genes and modulation of local tissue responses. In preclinical systems it has shown associations with reduced inflammatory markers and support for reparative activity in prostate tissue explants.
Experimental data indicate effects on ribosomal gene activity, chromatin remodeling in lymphocytes from elderly donors, and anti-inflammatory outcomes in rat models of prostatic inflammation, including reduced swelling, vascular congestion, immune cell infiltration, and scarring tendencies.
Integrated Research Applications
Prostamax is formulated to support focused investigation of short-peptide effects on prostate-related and aging-related pathways. Representative research domains include:
In vitro and organotypic models examining prostate explant growth, reparative activity, and cellular responses under controlled conditions.
Cell culture studies of chromatin structure, gene expression patterns, and age-related silencing in lymphocytes or other cells.
Preclinical animal models exploring inflammation reduction, tissue remodeling, and functional support in experimentally induced prostatitis or related conditions.
Using Prostamax as a single, well-characterized entity allows researchers to evaluate tissue-oriented signaling without the variability of complex tissue extracts.
Analytical Validation and Quality Assurance
Commercial research preparations of Prostamax are typically specified at high purity (often ≥98–99%) and characterized by HPLC and mass spectrometry. These methods confirm identity, sequence integrity, and batch consistency for laboratory use.
Product configurations commonly include lyophilized Prostamax powder in sealed glass vials, with labeling that documents peptide content (for example 20 mg), suggested reconstitution volumes, and research-use disclaimers. This supports standardized dosing across experiments.
Storage and Stability Guidelines
Proper storage preserves structural integrity and experimental reproducibility. Typical guidance for lyophilized Prostamax includes:
Room temperature (unopened, lyophilized): Suitable for limited periods when sealed, dry, and protected from light.
Refrigerated storage (2–8 °C): Appropriate for medium-term maintenance of unopened or reconstituted material used over days to weeks.
Frozen storage (≤ −20 °C, preferably lower for long-term): Recommended for extended timelines, with vials kept well sealed to limit moisture and degradation.
Reconstituted solutions are generally stored cold, protected from light, and used within a defined experimental window according to local lab practices to maintain activity and limit contamination risk.
